Strolll – Reality DTx

Reality DTx is cutting-edge digital therapeutic software, utilised by augmented reality (AR) headsets, that enables home-based neurorehabilitation.

With Reality DTx patients with Parkinson’s, those who live with MS and stroke survivors can access activities which improve their gait and balance and reduce their risk of falling, alongside improvement in clinical outcomes such as walking speed and mobility assessments. Users also report increased confidence, independence and enhanced quality of life.

Strolll has developed a cutting-edge digital therapeutic software with Reality DTx for augmented reality glasses and headsets to enable home-based neurorehabilitation for patients with neurological conditions.

Addressing an unmet healthcare need

Prevalence and Burden

Over 150,000 ⁽¹⁾ people in the UK have Parkinson’s, 1.3 million ⁽²⁾ people are stroke survivors and 150,000 ⁽³⁾ live with MS – many can face long-term impairments and reduced quality of life.

Barriers to rehabilitation and re-ablement

According to NHS England, access to rehabilitation services within the NHS is limited. Workforce and funding shortages and geographic disparities, combined with low adherence to traditional rehabilitation programmes ^(4), reduces outcomes for patients and health and care systems.

Economic impact

Neurological conditions cost the NHS £4.4 billion⁽⁵⁾ annually, including £2.3 billion⁽⁶⁾ for preventable falls. Ineffective rehabilitation prolongs recovery and increases reliance on acute care.

Strolll and Reality DTx support NHS operational planning guidance and the government’s prescribed ‘shifts’ for the NHS by

• Implementing digital innovation – supporting the shift from analogue to digital.
• Moving rehabilitation services into the community – enabling the shift from hospital to community.
• Supporting the management o long-term conditions – via remote monitoring.
• Improving productivity
• Transforming neuro-rehab services

Future plans

Stroll has secured £2.4 million in  NIHR funding for a Randomised Controlled Trial involving 216 patients across 3–4 sites is set to report in April 2025, further validating Reality DTx®’s clinical and economic impact.

The team’s next steps are further clinical trials (including 2025’s RCT), market expansion, further integration into care pathways and making the most of opportunities to scale both patient impact and the business internationally.